We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Centessa Pharmaceuticals PLC | NASDAQ:CNTA | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.36 | -3.16% | 11.04 | 11.08 | 11.67 | 11.61 | 10.95 | 11.42 | 332,516 | 01:00:00 |
From Aug 2022 to Aug 2024
By Colin Kellaher
Centessa Pharmaceuticals PLC on Wednesday said the U.S. Food and Drug Administration granted orphan-drug designation to its lead candidate SerpinPC for the treatment of the hereditary bleeding disorder hemophilia B.
The U.K.-based clinical-stage pharmaceutical company said it plans to begin registrational studies of SerpinPC in the fourth quarter.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 14, 2022 09:29 ET (13:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Centessa Pharmaceuticals Chart |
1 Month Centessa Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
